Stockscreener 앱 받기
3.60
2.27%
0.08
시간 외 거래:
3.60
전일 마감가:
$3.52
열려 있는:
$3.53
하루 거래량:
1.54M
Relative Volume:
0.67
시가총액:
$598.34M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.2857
EPS:
-2.8
순현금흐름:
$-304.44M
1주 성능:
+10.43%
1개월 성능:
+13.21%
6개월 성능:
-16.28%
1년 성능:
-44.36%
1일 변동 폭
$3.49
$3.75
1주일 범위
$3.20
$3.75
52주 변동 폭
$1.775
$10.72
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
3.60 | 598.34M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
In the Green: Relay Therapeutics Inc (RLAY) Closes at 3.06, Up/Down -6.42 from Previous Day - DWinneX
Relay Therapeutics’ SWOT analysis: AI-driven drug discovery stock faces pivotal phase - Investing.com India
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by California State Teachers Retirement System - Defense World
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus
Relay Therapeutics Appoints Claire Mazumdar to Board of Directors - citybiz
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com India
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial By Investing.com - Investing.com South Africa
Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - MarketScreener
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Bluefield Daily Telegraph
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 9,293 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Relay Therapeutics Holds 2025 Annual Stockholder Meeting - TipRanks
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Relay Therapeutics (RLAY) Gets a Hold from Wells Fargo - The Globe and Mail
Relay Therapeutics Announces Lease Termination Agreement - TipRanks
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DE - Defense World
Citizens JMP maintains Relay Therapeutics stock rating after trial data By Investing.com - Investing.com Canada
Nuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Jane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics reports promising breast cancer drug data By Investing.com - Investing.com South Africa
Relay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast Cancer - Insider Monkey
Relay Therapeutics, Inc. Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival At Asco 2025 - MarketScreener
Relay Therapeutics (RLAY) Shares Positive Interim Results for RL - GuruFocus
Relay Therapeutics reports promising breast cancer drug data - Investing.com Australia
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | RLAY Stock News - GuruFocus
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 - TradingView
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by ProShare Advisors LLC - Defense World
Deutsche Bank AG Purchases 30,278 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Ameriprise Financial Inc. Purchases 28,989 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 17,009 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June - The Manila Times
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June | RLAY Stock News - GuruFocus
Relay Therapeutics Management to Share Latest Precision Medicine Strategy at Two Major Healthcare Conferences - Stock Titan
Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year - Investing.com Nigeria
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders - Quantisnow
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders – Company Announcement - Financial Times
Man Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
What Makes Relay Therapeutics (RLAY) a New Buy Stock - MSN
Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Stifel Financial Corp Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Transcript : Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
355,376 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 29 '25 |
Sale |
3.23 |
3,558 |
11,492 |
368,319 |
| Catinazzo Thomas | Chief Financial Officer |
Apr 28 '25 |
Sale |
3.17 |
2,690 |
8,527 |
371,877 |
| Bergstrom Donald A | President, R&D |
Apr 30 '25 |
Sale |
3.00 |
27,472 |
82,416 |
583,490 |
| Bergstrom Donald A | President, R&D |
Apr 28 '25 |
Sale |
3.17 |
4,090 |
12,965 |
610,962 |
| Adams Brian | Chief Legal Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
391,385 |
| Adams Brian | Chief Legal Officer |
Apr 28 '25 |
Sale |
3.17 |
1,644 |
5,211 |
404,328 |
1.45%
0.86%
자본화:
|
볼륨(24시간):